Clinical Study Identifies Personalized Treatment Options for Metastatic Non-Small Cell Lung Cancer With Plasma Proteome Testing
FORT MYERS, Fla., April 25, 2024. Florida Cancer Specialists& Research Institute, LLC (FCS) medical oncologist and hematologist Ernesto Bustinza-Linares, MD is co-author of a recent abstract published in the American Society of Clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Gene-Based Therapy Restores Cellular Development and Function in Brain Cells From People With Timothy Syndrome
April 24, 2024 -- In a proof-of-concept study, researchers demonstrated the effectiveness of a potential new therapy for Timothy syndrome, an often life-threatening and rare genetic disorder that affects a wide range of bodily systems, leading to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 24, 2024 Category: Pharmaceuticals Source Type: clinical trials
Lykos Therapeutics Announces Completion of European Phase 2 Study for MDMA-Assisted Therapy for PTSD
SAN JOSE, Calif., April 24, 2024. Lykos Therapeutics (formerly MAPS Public Benefit Corporation) ( " Lykos " ), a company dedicated to transforming mental healthcare, announced the completion of a European Phase 2 study (MP18), an open-label, multicenter... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 24, 2024 Category: Pharmaceuticals Source Type: clinical trials
Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Leukemia, Myeloid, Acute Interventions: Drug: DFP-10917; Drug: Venetoclax Sponsors: Delta-Fly Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Study to Assess PK, Safety and Tolerability in Healthy Subjects
Conditions: Acute Ischemic Stroke Interventions: Drug: QHRD106 Injection; Drug: Yurekline; Drug: placebo Sponsors: Changzhou Qianhong Bio-pharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Endevica Bio drug candidate shows success in weight loss in new study
NORTHBROOK, Ill., April 23, 2024 - Endevica Bio, a company developing first-in-class peptide drug candidates, announced its novel weight-loss treatment was successful in a recent diet-induced obesity (DIO) rat study.
This latest research solidifies... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 23, 2024 Category: Pharmaceuticals Source Type: clinical trials
FDA Approves Clinical Trial for GFH925 Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
SHANGHAI, April 19, 2024. GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 22, 2024 Category: Pharmaceuticals Source Type: clinical trials
ICP-248 in Combination With Orelabrutinib in Treatment-na ïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Hematologic Malignancies Interventions: Drug: ICP-248; Drug: Orelabrutinib Sponsors: Beijing InnoCare Pharma Tech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Doctors Underutilize Next-Gen Antibiotics to Fight Resistant Infections in U.S. Hospitals
April 19, 2024 -- Despite Food and Drug Administration (FDA)-approval of seven next-generation antibiotics to fight infections caused by resistant“gram-negative” bacteria, clinicians frequently continue to treat antibiotic-resistant... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 19, 2024 Category: Pharmaceuticals Source Type: clinical trials
AskBio Receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure
Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024– Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
NIH Researchers Develop AI Tool with Potential to More Precisely Match Cancer Drugs to Patients
April 18, 2024 -- In a proof-of-concept study, researchers at the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person’s cancer... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON--(BUSINESS WIRE)--Apr. 18, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
BiVictriX Announces FDA Orphan Drug Designation and Completion of FDA INTERACT Meeting for BVX001 in the Treatment of Acute Myeloid Leukemia
Alderley Park, 17 April 2024– BiVictriX Therapeutics plc (AIM: BVX), a biotechnology company developing novel, next-generation bispecific Antibody Drug Conjugates (bxADCs) which are designed to offer substantially improved cancer cell... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 17, 2024 Category: Pharmaceuticals Source Type: clinical trials
EAGLE-1 Phase III Data Show Potential for Gepotidacin as a New Oral Treatment Option for Uncomplicated Urogenital Gonorrhoea (GC) Amid Growing Resistance to Existing Treatments
17 April 2024 -- GSK plc (LSE/NYSE: GSK) today announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 17, 2024 Category: Pharmaceuticals Source Type: clinical trials
Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design
Conditions: Erythema Interventions: Drug: MOB015B; Drug: MOB015B vehicle; Drug: Negative irritant solution of 0.9% saline Sponsors: Moberg Pharma AB Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
